Hear+Now: An AI-Powered Audio Digest – Patients Who Have Stopped Disease-Modifying Therapy
A significant share of patients with multiple sclerosis are no longer on disease-modifying therapy — but the reasons behind that vary widely, from a deliberate, monitored decision to a stop that simply happened years ago and was never revisited. This audio digest examines how those different paths lead to very different clinical situations, and why distinguishing between them matters more than the surface fact of being off therapy. Listen in to learn more.
This audio digest was generated with the assistance of an AI tool and reviewed by a member of our Editorial Team and Health Union Medical Review Board. This information is provided for general knowledge and is not a substitute for professional medical advice.
Transcript:
Speaker 1: Today we're talking about multiple sclerosis and patients who have stopped disease-modifying therapy. We are pulling from the 2026 Multiple Sclerosis In America survey and recent clinical trial data to map out the sheer size of this off-therapy population. We will try to understand why these stops occur and examine what happens clinically when they do.
Speaker 2: So the first step is looking at the size and shape of this group. The 2026 Multiple Sclerosis in America survey shows about 32 percent of respondents with relapsing forms of MS had used a therapy in the past, but were not on one at the time of the survey.
Speaker 1: Compared to about 8 percent who had never used one at all.
Speaker 2: Exactly. And the numbers shift even higher depending on the disease course. For respondents with secondary progressive disease, the figure sits at about 46 percent. And even among relapsing-remitting respondents reporting no relapses in the past year, about a quarter were off therapy. So what stands out is that this is not a treatment-naive group. This is a population with significant treatment history.
Speaker 1: Right. The mean age is about 59, and the mean time since diagnosis is roughly 20 years. It is a long history. But for providers walking into the exam room, it is easy to only see the current surface layer, like the fact that the patient is currently off therapy. But digging down reveals a treatment history built up over decades.
Speaker 2: And analyzing the open-ended survey responses shows how patients arrive at this off-therapy status. The stops usually fall into a few distinct patterns. For instance, age often serves as a definitive catalyst. One respondent described stopping therapy precisely at age 65, reporting no major issues since crossing that threshold.
Speaker 1: But age is just one catalyst. Accumulated intolerance drives another pattern.
Speaker 2: Yeah, over decades of disease management, minor sensitivities compound. Another respondent detailed becoming increasingly sensitive to medication side effects over time, eventually reaching a point of being unable to tolerate many therapies at all.
Speaker 1: And then there's the stop that simply happened and was never revisited.
Speaker 2: Right. The survey captured a response from a patient with secondary progressive disease 41 years past diagnosis. Her biggest challenge was just getting her neurologist to listen and understand the need for disease-modifying medicine again after years without it.
Speaker 1: So how do patient experiences align with recent controlled clinical trial data on discontinuation risk? Do the trials support these stops?
Speaker 2: Well, the clinical data establishes very clear parameters regarding the risks, especially when examining first-line therapies. A randomized trial looked at discontinuing first-line therapy in patients who had been stable for at least five years with a median age of 54.
Speaker 1: Yeah and that trial actually had to be stopped early.
Speaker 2: It did. The recurrence in the discontinuation arm exceeded predefined limits. Specifically, eight of 45 patients who stopped therapy had new disease activity.
Speaker 1: Compared to zero of 44 patients who continued.
Speaker 2: Right. But breaking down those eight events provides essential context. Six of the eight events were radiological only, meaning there were just two clinical relapses across the entire trial.
Speaker 1: So the recurrence was largely smoldering beneath the surface radiologically rather than manifesting as outright clinical relapse?
Speaker 2: Exactly. Because of that, the trial authors still describe a monitored attempt at discontinuation as a viable option.
Speaker 1: Further context emerges from an observational study of patients 50 and older who had been free of activity for at least two years.
Speaker 2: Yeah, that data demonstrated roughly four times the relapse risk after stopping high-efficacy therapy. But, you know, it is critical to understand the mechanism behind that risk.
Speaker 1: Because the increased relapse rate was not uniform across the entire class of therapies.
Speaker 2: Right. The risk was highly concentrated in specific mechanisms, primarily natalizumab and sphingosine 1-phosphate receptor modulators.
Speaker 1: To clarify how that works, sphingosine 1 phosphate receptor modulators function by trapping immune cells within the lymph nodes. Discontinuing that specific mechanism suddenly releases those sequestered cells back into circulation.
Speaker 2: Which can trigger a severe physiological rebound effect. The physiological rebound explains the concentrated risk. Consequently, the observational finding does not serve as evidence that stopping is universally safe for any particular agent.
Speaker 1: This data reflects a critical clinical distinction for providers. An off-therapy status that was deliberately decided, documented, and is being actively monitored is a completely different clinical situation from a discontinuation that simply happened over time.
Speaker 2: And a standard clinical visit rarely separates those two scenarios automatically.
Speaker 1: Therefore, the primary task for providers is establishing exactly which of the two situations sits in front of them and taking next steps from there.